Phio Pharmaceuticals Corp (PHIO): Price and Financial Metrics


Phio Pharmaceuticals Corp (PHIO): $6.16

-0.44 (-6.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PHIO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PHIO Stock Price Chart Interactive Chart >

Price chart for PHIO

PHIO Price/Volume Stats

Current price $6.16 52-week high $29.04
Prev. close $6.60 52-week low $3.90
Day low $6.14 Volume 50,700
Day high $6.57 Avg. volume 62,456
50-day MA $5.42 Dividend yield N/A
200-day MA $7.51 Market Cap 7.01M

Phio Pharmaceuticals Corp (PHIO) Company Bio


Phio Pharmaceuticals Corp operates as a pharmaceutical company. The Company focuses on cancer immunotherapy, as well as offers medicine for other diseases. Phio Pharmaceuticals serves customers in the United Sates.


PHIO Latest News Stream


Event/Time News Detail
Loading, please wait...

PHIO Latest Social Stream


Loading social stream, please wait...

View Full PHIO Social Stream

Latest PHIO News From Around the Web

Below are the latest news stories about PHIO PHARMACEUTICALS CORP that investors may wish to consider to help them evaluate PHIO as an investment opportunity.

Phio Pharmaceuticals Announces Reverse Stock Split

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-12. The reverse stock split will become effective at 12:01 a.m. Eastern Time on January 26, 2023 and the Company's common stock will open for trading on Th

Yahoo | January 25, 2023

Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco

Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that its Principal Executive Officer and Executive Chairman, Robert Bitterman, will be a featured speaker at the Entrepreneurial Showcase at the Dermatology Summit in San Francisco on January 8th. The Dermatology Summit is taking place at the Hyatt Regency, alongside the annual JPMor

Yahoo | January 6, 2023

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today announced their clinical development partner, AgonOx, Inc. has received confirmation from the FDA that their planned Phase 1 clinical trial in patients with advanced solid tumors may proceed. The initial Phase 1 clinical trial is designed to assess safety and to study the potential for an enhanced therapeutic benefit from the administration of Phio's PH-762 treated "double positive" (DP) CD8 tumor infiltrating lymphocyte (TIL) in patients with mela

Yahoo | January 6, 2023

Have you been able to find a good deal on Phio Pharmaceuticals Corp.’s shares?

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) marked $0.38 per share on Wednesday, up from a previous closing price of $0.36. While Phio Pharmaceuticals Corp. has overperformed by 3.56%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PHIO fell by -68.22%, with highs and lows ranging from $2.42 to […]

US Post News | December 22, 2022

Phio Pharmaceuticals Outlines New PH-762 Program For Common Skin Cancer In US Patients

Phio Pharmaceuticals Corp (NASDAQ: PHIO) said it expects to file an IND in the U.S. in the first half of 2023 for a Phase 1b clinical trial of its INTASYL compound, PH-762. Phio is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in killing tumor cells. PH-762 has been shown to reduce the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. When administered intratumorall

Yahoo | December 22, 2022

Read More 'PHIO' Stories Here

PHIO Price Returns

1-mo -15.85%
3-mo -11.72%
6-mo -33.15%
1-year -42.94%
3-year -93.11%
5-year -99.72%
YTD 37.99%
2022 -62.80%
2021 -62.83%
2020 -71.40%
2019 -48.18%
2018 -94.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7315 seconds.